Crossmark

Proportions of patients meeting definitions for progressive disease or improvement should be included in clinical trials for systemic sclerosis interstitial lung disease

Crossref DOI link: https://doi.org/10.1186/s13075-026-03803-z

Published Online: 2026-04-14

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Morrisroe, Kathleen

Tashkin, Donald

Baron, Murray
Funding

Funding for this research was provided by:

National Health and Medical Research Council (GNT1197169)
License Information

Text and Data Mining valid from 2026-04-14

Version of Record valid from 2026-04-14
More Information

Article History

Received: 13 January 2026

Accepted: 23 March 2026

First Online: 14 April 2026

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below